Picamilon in stage I and II chronic cerebral ischemia: open comparative study

A. B. Danilov, N. N. Shindryaeva, I. V. Borodulina, T. D. Lunev · 2025 · Consilium Medicum. 2025;27(2)

Uncontrolled human reportFull text availableSource linked

This is Molekul’s research summary, not the original publication. Educational information only, not medical advice. Seek qualified healthcare help for medical conditions.

What does this source report?

Open study reported cognitive and questionnaire changes during active treatment. Six participants did not complete; efficacy used the per-protocol population.

Population and setting: 100 enrolled; 94 in per-protocol efficacy analysis; stage I and II groups initially 50 each
Evidence type: Uncontrolled human report
Preparation: See the original report; formulation details require verification.
Source language: See linked publication
Title provenance: Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.

What are the limitations?

No untreated or placebo group.
Shared investigators, protocols and cohort characteristics suggest possible overlap with the 2024 reports; this is an inference, not confirmed participant identity.
Do not add 44, 50 and 100 as independent participants.

Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.

Document format: Publisher HTML article

Review depth: Methods and results

Related-report group: picamilon-2024-2025-overlap-unresolved. Reports in this group are not assumed to be independent trials.

Source access and review scope

Publisher methods and results checked; participant-level reconciliation with 2024 reports remains unresolved.

Recorded source-check date: 2026-10-02. This date does not imply a completed systematic review.

Open original source or index record ↗

DOI: 10.26442/20751753.2025.2.203195

Cite and trace this record

Original source: A. B. Danilov, N. N. Shindryaeva, I. V. Borodulina, T. D. Lunev. Picamilon in stage I and II chronic cerebral ischemia: open comparative study Consilium Medicum. 2025;27(2) 2025.

Molekul research summary: https://molekul.io/research/picamilon-2025-cohort. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.

Bibliography entry

Related compound profiles

Picamilon

A synthetic nicotinoyl-GABA compound connecting Soviet cerebrovascular pharmacology with later swimmer, clinical and occupational research. Shustov lists it as an alternative in a proposed mental-work framework; no Picamilon shipboard trial is established here.

Editorial policy and evidence standards